Abstract:Continuous loss of cardiomyocytes (CMs) is one of the fundamental characteristics of many heart diseases, which eventually can lead to heart failure. Due to the limited proliferation ability of human adult CMs, treatment efficacy has been limited in terms of fully repairing damaged hearts. It has been shown that cell lineage conversion can be achieved by using cell reprogramming approaches, including human induced pluripotent stem cells (hiPSCs), providing a promising therapeutic for regenerative heart medicine. Recent studies using advanced cellular reprogramming-based techniques have also contributed some new strategies for regenerative heart repair. In this review, hiPSC-derived cell therapeutic methods are introduced, and the clinical setting challenges (maturation, engraftment, immune response, scalability, and tumorigenicity), with potential solutions, are discussed. Inspired by the iPSC reprogramming, the approaches of direct cell lineage conversion are merging, such as induced cardiomyocyte-like cells (iCMs) and induced cardiac progenitor cells (iCPCs) derived from fibroblasts, without induction of pluripotency. The studies of cellular and molecular pathways also reveal that epigenetic resetting is the essential mechanism of reprogramming and lineage conversion. Therefore, CRISPR techniques that can be repurposed for genomic or epigenetic editing become attractive approaches for cellular reprogramming. In addition, viral and non-viral delivery strategies that are utilized to achieve CM reprogramming will be introduced, and the therapeutic effects of iCMs or iCPCs on myocardial infarction will be compared. After the improvement of reprogramming efficiency by developing new techniques, reprogrammed iCPCs or iCMs will provide an alternative to hiPSC-based approaches for regenerative heart therapies, heart disease modeling, and new drug screening.

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

Induced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives

Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells

The Challenges Of Stem Cell Therapy In Myocardial Infarction And Heart Failure And The Potential Strategies To Improve The Outcomes

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Stem cell therapy for cardiac regeneration: past, present, and future

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?

Potential Applications Of Induced Pluripotent Stem Cells For Cardiovascular Diseases

Current Status of Induced Pluripotent Stem Cells in Cardiac Tissue Regeneration and Engineering.

Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy

Regenerative Therapy for Cardiomyopathies

Non-viral approaches for somatic cell reprogramming into cardiomyocytes.

Progress in preclinical research on induced pluripotent stem cell therapy for acute myocardial infarction

Recent advances and future prospects in direct cardiac reprogramming

Pluripotent Reprogramming and Lineage Reprogramming: Promises and Challenges in Cardiovascular Regeneration

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery